Akèy › Kansè Poumon ki pa ti selil › Colorado › Aurora
Etid klinik pou Kansè Poumon ki pa ti selil nan Aurora, CO
31 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Aurora (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Ap rekriteFaz 1/2
- University Of Colorado - Anschutz Medical Campus /ID# 269069, Aurora
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Rocky Mountain Cancer Centers-Aurora, Aurora
- UCHealth University of Colorado Hospital, Aurora
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Colorado, Aurora
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- University of Colorado Anschutz Medical Campus ( Site 0151), Aurora
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- University of Colorado Cancer Center ( Site 3268), Aurora
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Rocky Mountain Cancer Centers LLP, Aurora
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Ap rekriteFaz 1/2
- Rocky Mountain Cancer Centers,LLP, Aurora
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- University of Colorado Cancer Center, Aurora
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Ap rekriteFaz 1
- University of Colorado Cancer Center, Aurora
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Aurora
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Ap rekriteFaz 1/2
- University of Colorado - Aurora Cancer Center, Aurora
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Local Institution - 007-872-H, Aurora
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- University of Colorado, Aurora
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- University of Colorado Cancer Center, Aurora
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Colorado Health Hospital, Aurora
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- University of Colorado Cancer Center, Aurora
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- University of Colorado Health, Aurora
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Colorado, Aurora
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Ap rekriteFaz 1/2
- University of Colorado Cancer Center, Aurora
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora
- University of Colorado Hospital, Aurora
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- UCHealth University of Colorado Hospital, Aurora
Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.
Ap rekriteEtid obsèvasyon
- University of Colorado Hospital, Aurora
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Rocky Mountain Regional VA Medical Center, Aurora
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- UCHealth University of Colorado Hospital, Aurora
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Ap rekriteFaz 1/2
- University of Colorado Cancer Center, Aurora
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Rocky Mountain Cancer Centers-Aurora, Aurora
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Ap rekriteEtid obsèvasyon
- University of Colorado, Cancer Center, Aurora
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Aurora
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Ap rekriteEtid obsèvasyon
- University of Colorado Cancer Center at UC Health Sciences Center, Aurora
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of Colorado School of Medicine, Aurora
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Aurora
- Kansè (tout kalite)35 etid
- Kansè kolorektal32 etid
- Kansè nan tete28 etid
- Kansè ovè25 etid
- Kansè Metastatik25 etid
- Dyabèt tip 123 etid
- Obèsite22 etid
- Kansè pwostat19 etid
- Kansè poumon19 etid
- Ensifizyans kadyak18 etid
- Melanom18 etid
- Leksemi mieloïd egi16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.